Stereotactic body radiation therapy for hepatocellular carcinoma: From infancy to ongoing maturity.
Ontology highlight
ABSTRACT: Hepatocellular carcinoma (HCC) accounts for 90% of liver tumours and is one of the leading causes of mortality. Cirrhosis due to viral hepatitis, alcohol or steatohepatitis is the major risk factor, while liver dysfunction due to cirrhosis is a deciding factor in its treatment. The treatment modalities for HCC include liver transplant, hepatectomy, radiofrequency ablation, transarterial chemoembolisation, transarterial radioembolisation, targeted therapy, immunotherapy, and radiation therapy. The role of radiation therapy has been refined with the increasing use of stereotactic body radiation therapy (SBRT). Trials over the past two decades have shown the efficacy and safety of SBRT in recurrent and definitive HCC, leading to its acceptance and adoption in some more recent guidelines. Howe
SUBMITTER: Lewis S
PROVIDER: S-EPMC9289870 | biostudies-literature | 2022 Aug
REPOSITORIES: biostudies-literature
ACCESS DATA